GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Phase 1

Completed

Conditions: Infections, Meningococcal

Interventions: Combination Product: MenABCWY-2Gen low dose vaccine
Combination Product: Placebo
Combination Product: MenABCWY-2Gen high dose vaccine
Combination Product: MenB vaccine
Biological: MenACWY vaccine

First Posted Date: 2021-05-13

Last Posted Date: 2025-02-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1440

Registration Number: NCT04886154

Locations: 🇹🇷
GSK Investigational Site, Kocaeli, Turkey

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Capoten
Drug: Captopril

First Posted Date: 2021-05-07

Last Posted Date: 2023-01-27

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT04878315

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

Phase 4

Completed

Conditions: Herpes Zoster

Interventions: Biological: RZV
Drug: Placebo

First Posted Date: 2021-05-03

Last Posted Date: 2025-01-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6138

Registration Number: NCT04869982

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: Prospective observational cohort study

First Posted Date: 2021-04-21

Last Posted Date: 2024-12-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1507

Registration Number: NCT04853238

Locations: 🇨🇳
GSK Investigational Site, Zhengzhou, China

Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: Prospective observational cohort study

First Posted Date: 2021-04-21

Last Posted Date: 2025-05-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2000

Registration Number: NCT04853225

Locations: 🇨🇳
GSK Investigational Site, Zhuhai, China

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine
Biological: FLU-QIV

First Posted Date: 2021-04-12

Last Posted Date: 2022-10-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 976

Registration Number: NCT04841577

Locations: 🇿🇦
GSK Investigational Site, Middelburg, Mpumalanga, South Africa

A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Device: ELLIPTA
Device: BREEZHALER

First Posted Date: 2021-03-24

Last Posted Date: 2023-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 114

Registration Number: NCT04813354

Locations: 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Phase 2

Completed

Conditions: Influenza, Human

Interventions: Biological: FLU-Q-PAN H7N9 Formulation 1
Biological: FLU-Q-PAN H7N9 Formulation 2
Biological: FLU-Q-PAN H7N9 Formulation 3
Drug: Placebo
Biological: AS03A
Biological: AS03B

First Posted Date: 2021-03-09

Last Posted Date: 2023-10-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 833

Registration Number: NCT04789577

Locations: 🇺🇸
GSK Investigational Site, West Jordan, Utah, United States

Molecular Disease Characterization Initiative (MDCI)

Phase 2

Terminated

Conditions: Lung Cancer, Non-Small Cell
Neoplasms

Interventions: Procedure: Tumor biopsy

First Posted Date: 2021-02-26

Last Posted Date: 2024-04-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT04772053

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Phase 1

Terminated

Conditions: Herpes Simplex

Interventions: Drug: Placebo (saline)
Biological: Low dose formulation of HSV vaccine (GSK4108771A)
Biological: Medium dose formulation of HSV vaccine (GSK4108771A)
Biological: High dose formulation of HSV vaccine (GSK4108771A)
Biological: Lower dose formulation of HSV vaccine (GSK4108771A)

First Posted Date: 2021-02-21

Last Posted Date: 2021-06-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 17

Registration Number: NCT04762511

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

Home Terms & Conditions Privacy Policy